Focus: Neurelis is a micro-cap biotech focused on licensing, developing, and commercializing product candidates in neurology and psychiatry. The company operates as a single-product entity with minimal scale (1-50 employees) based in San Diego.
Profile data last refreshed 20h ago · AI intelligence enriched 2w ago
Stable — net +2 jobs in 30d
2 added, 0 removed. Backfill posture.
Neurelis is a high-risk/high-reward micro-cap suitable only for professionals seeking early-stage exposure and outsized impact in exchange for significant financial and career instability.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Neurelis
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Neurelis's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Only marketed product; generates 100% of company revenue with 6+ years remaining patent exclusivity.
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo